Returning back in 2019

Shanghai, China

2018 Speakers

Expand/Collapse

Junho Chung
Professor
Seoul National University College of Medicine

Conference Day Two

Thursday, 27th September 2018

14.45 | Preclinical Development of Anti-HGF (Hepatocyte Growth Factor) Antibody

Bingliang Chen
Chief Scientist
Innovent Biologics

Conference Day Two

Thursday, 27th September 2018

14.15 | Case Study: TNFR-Superfamily Members OX40 Combination with anti- PD-1 in Humanized Mouse Model

Kerry Blanchard
Kerry Blanchard
Innovent Biologics

Conference Day Two

Thursday, 27th September 2018

10.35 | Panel Discussion: What is the Future of Immuno-oncology in Asia, in the Context of the Rapidly Changing Regulatory environment and Unique Biotech Landscape in Asia?

09.35 | Which Problem Should We Fix: The Targets, the Models or Both?

Juan Liu
Head of External Collaborations
Pfizer China

Conference Day One

Wednesday, 26th September 2018

09.40 | Opening Talk: The State of Play for Preclinical Oncology Modelling in Asia

Pengfei Zhou
CEO
YZY Biopharma

Conference Day Two

Thursday, 27th September 2018

11.45 | Case Study: Preclinical Development of T-Cell Redirecting Bispecific Antibodies

Xuan Wu
Director of Biology
EpimAb Biotherapeutics

Conference Day Two

Thursday, 27th September 2018

13.45 | EMB-01: An Innovative cMet/EGFR Bispecific Antibody Targeting NSCLC

10.35 | Panel Discussion: What is the Future of Immuno-oncology in Asia, in the Context of the Rapidly Changing Regulatory environment and Unique Biotech Landscape in Asia?

Davy Ouyang
Senior Director
Crown Bioscience

Conference Day One

Wednesday, 26th September 2018

10.10 | Keynote Talk: Developing Mouse Tumor Homograft Model Platform (MuPrime) for Immuno-Oncology Drug Discovery

James Keck
Senior Director In Vivo Pharmacology
The Jackson Laboratory

Pre Conference Workshop

Tuesday, 25th September 2018

09.30 | Guide to Utilising Humanized Mice for Your Immuno-Oncology Preclinical Research for Increased Translational Success

Conference Day One

Wednesday, 26th September 2018

12.30 | Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice: A New Immuno-Oncology Platform

Lisa Ooi
Scientific Director
ASLAN Pharma

Conference Day One

Wednesday, 26th September 2018

12.00 | In Vivo Modelling for Testing of a Novel Metabolic Pathway

Paula Lam
Head, RnD, Stem Med Pte. Ltd.
Duke – NUS

Conference Day One

Wednesday, 26th September 2018

14.30 | Understanding the Biological Effects of Mesenchymal Stem Cells and their Effect on Different Tumor Microenvironments

Hongtao Lu
CSO & Co-Founder
Elpiscience

Conference Day Two

Thursday, 27th September 2018

12.15 | Challenge and opportunity in animal models for immuno-oncology

10.35 | Panel Discussion: What is the Future of Immuno-oncology in Asia, in the Context of the Rapidly Changing Regulatory environment and Unique Biotech Landscape in Asia?

Laura Benjamin
CSO & Co-Founder
Oncologie International

Conference Day One

Wednesday, 26th September 2018

16.30 | Using Data Gained from Preclinical Mouse Models to Better Inform Biomarker and Patient Selection

Ramanuj DasGupta
Senior Investigator/ Group Leader
Cancer Therapeutics and Stratified Oncology Genome Institute of Singapore, A*STAR